Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $5.5 million.

  • Apellis Pharmaceuticals' Other Non-Current Assets rose 27868.97% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 27868.97%. This contributed to the annual value of $1.3 million for FY2024, which is 305.58% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Other Non-Current Assets stood at $5.5 million, which was up 27868.97% from $898000.0 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Other Non-Current Assets ranged from a high of $5.5 million in Q3 2025 and a low of $898000.0 during Q2 2025
  • Moreover, its 5-year median value for Other Non-Current Assets was $1.3 million (2024), whereas its average is $1.5 million.
  • Within the past 5 years, the most significant YoY rise in Apellis Pharmaceuticals' Other Non-Current Assets was 27868.97% (2025), while the steepest drop was 3293.5% (2025).
  • Apellis Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $1.6 million in 2021, then fell by 18.55% to $1.3 million in 2022, then rose by 2.83% to $1.3 million in 2023, then rose by 3.06% to $1.3 million in 2024, then soared by 307.04% to $5.5 million in 2025.
  • Its Other Non-Current Assets was $5.5 million in Q3 2025, compared to $898000.0 in Q2 2025 and $1.4 million in Q1 2025.